143 related articles for article (PubMed ID: 12975722)
21. Costs and benefits in switching from Rx to OTC.
Temin P
J Health Econ; 1983 Dec; 2(3):187-205. PubMed ID: 10310393
[TBL] [Abstract][Full Text] [Related]
22. Advisory committees; OTC Drugs Advisory Committee; establishment--FDA. Final rule.
Fed Regist; 1991 Sep; 56(185):48103-4. PubMed ID: 10114368
[TBL] [Abstract][Full Text] [Related]
23. The US Food and drug administration: drug information resource for formulary recommendations.
Marchand HC; Ros BJ; Fine AM; Kremzner ME
J Manag Care Pharm; 2012; 18(9):713-8. PubMed ID: 23206214
[TBL] [Abstract][Full Text] [Related]
24. The treatment of gastroesophageal reflux disease with proton-pump inhibitors and its implications on managed care--pharmacoeconomics and its application to antisecretory drugs: a case study.
Morreale A
Manag Care Interface; 2001; Suppl B():28-30; discussion 31-3. PubMed ID: 11569296
[No Abstract] [Full Text] [Related]
25. The conversion of a prescription drug to OTC Status.
Aschenbrenner DS
Am J Nurs; 2007 Mar; 107(3):54-5. PubMed ID: 17314558
[TBL] [Abstract][Full Text] [Related]
26. From prescription-only (Rx) to over-the-counter (OTC) status in Germany 2006-2015: pharmacological perspectives on regulatory decisions.
Barrenberg E; Garbe E
Eur J Clin Pharmacol; 2017 Jul; 73(7):901-910. PubMed ID: 28352949
[TBL] [Abstract][Full Text] [Related]
27. Impact of the reclassification of omeprazole on the prescribing and sales of ulcer healing drugs.
Dhippayom T; Walker R
Pharm World Sci; 2006 Aug; 28(4):194-8. PubMed ID: 17066243
[TBL] [Abstract][Full Text] [Related]
28. [Effectiveness, safety, and costs of measures for prevention of gastropathy due to the use of nonsteroidal antiinflammatory drugs].
Salentijn GJ
Ned Tijdschr Geneeskd; 1999 Nov; 143(46):2340. PubMed ID: 10589227
[No Abstract] [Full Text] [Related]
29. Generic omeprazole delayed-release capsules: in vitro performance evaluations.
Moore T; Smith A; Ye W; Toler DY; Westenberger BJ; Lionberger R; Raw A; Yu L; Buhse LF
Drug Dev Ind Pharm; 2009 Aug; 35(8):917-21. PubMed ID: 19555236
[TBL] [Abstract][Full Text] [Related]
30. Antibiotic therapy of Helicobacter pylori infection reduces healthcare expenditures related to duodenal ulcer.
Sonnenberg A; Pauly MP; Levenson SD; Schwartz JS
Am J Manag Care; 1999 Jan; 5(1):53-9. PubMed ID: 10345967
[TBL] [Abstract][Full Text] [Related]
31. The debate continues on OTC switches.
Giaquinta D
Manag Care Interface; 2003 Jun; 16(6):49-50. PubMed ID: 12841076
[No Abstract] [Full Text] [Related]
32. The effect of the Rx-to-OTC switch of loratadine and changes in prescription drug benefits on utilization and cost of therapy.
Sullivan PW; Nair KV; Patel BV
Am J Manag Care; 2005 Jun; 11(6):374-82. PubMed ID: 15974556
[TBL] [Abstract][Full Text] [Related]
33. FDA panel advises against omeprazole as over the counter drug.
Gottlieb S
BMJ; 2000 Nov; 321(7269):1099. PubMed ID: 11061726
[No Abstract] [Full Text] [Related]
34. Women's health and the FDA.
Wood SF
N Engl J Med; 2005 Oct; 353(16):1650-1. PubMed ID: 16236734
[No Abstract] [Full Text] [Related]
35. The cost of long term therapy for gastro-oesophageal reflux disease: a randomised trial comparing omeprazole and open antireflux surgery.
Myrvold HE; Lundell L; Miettinen P; Pedersen SA; Liedman B; Hatlebakk J; Julkunen R; Levander K; Lamm M; Mattson C; Carlsson J; Ståhlhammar NO;
Gut; 2001 Oct; 49(4):488-94. PubMed ID: 11559644
[TBL] [Abstract][Full Text] [Related]
36. Are prescribed and over-the-counter medicines economic substitutes? A study of the effects of health insurance on medicine choices by the elderly.
Stuart B; Grana J
Med Care; 1995 May; 33(5):487-501. PubMed ID: 7739273
[TBL] [Abstract][Full Text] [Related]
37. South Dakota Medicaid will now cover OTC Loratadine and OTC Prilosec.
Brandenburg V; Darger D; Christianson H; Goeden G; Engelbrecht J; Hedge D; Holm R; Ladwig W;
S D J Med; 2005 Jan; 58(1):17. PubMed ID: 15696732
[No Abstract] [Full Text] [Related]
38. Unapproved prescription cough, cold, and allergy drug products: recent US Food and Drug Administration regulatory action on unapproved cough, cold, and allergy medications.
Ostroff C; Lee CE; McMeekin J
Chest; 2011 Aug; 140(2):295-300. PubMed ID: 21813527
[TBL] [Abstract][Full Text] [Related]
39. A pharmacoeconomic comparison of the efficacy and costs of pantoprazole and omeprazole for the treatment of peptic ulcer or gastroesophageal reflux disease in The Netherlands.
van Hout BA; Klok RM; Brouwers JR; Postma MJ
Clin Ther; 2003 Feb; 25(2):635-46. PubMed ID: 12749518
[TBL] [Abstract][Full Text] [Related]
40. Factors influencing the shift of patients from one proton pump inhibitor to another: the effect of direct-to-consumer advertising.
Hansen RA; Shaheen NJ; Schommer JC
Clin Ther; 2005 Sep; 27(9):1478-87. PubMed ID: 16291421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
